ethyl 3-(4-chlorophenyl)-5-methylisothiazole-4-carboxylate | 1172589-75-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 3-(4-chlorophenyl)-5-methylisothiazole-4-carboxylate
• 英文别名: 3-(4-chloro-phenyl)-5-methyl-isothiazole-4-carboxylic acid ethyl ester；Ethyl 3-(4-chlorophenyl)-5-methyl-1,2-thiazole-4-carboxylate
• CAS: 1172589-75-1
• 化学式: C₁₃H₁₂ClNO₂S
• 分子量: 281.763
• InChiKey: OSQOFVJKHYLXIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-(4-chlorophenyl)-5-methylisothiazole-4-carboxylate 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 (3-(4-chlorophenyl)-5-methylisothiazol-4-yl)methanol
  参考文献：
  名称：

  Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes

  摘要：

  We have discovered a novel series of isothiazole-based phenylpropanoic acids as GPR120 agonists. Extensive structure activity relationship studies led to the discovery of a potent GPR120 agonist 4x, which displayed good EC50 values in both calcium and beta-arrestin assays. It also presented good pharmaceutical properties and a favorable PK profile. Moreover, it demonstrated in vivo antidiabetic activity in C57BL/6 DIO mice. Studies in WT and knockout DIO mice showed that it improved glucose handling during an OGTT via GPR120. Overall, 4x possessed promising antidiabetic effect and good safety profile to be a development candidate.

  DOI：

  10.1021/acsmedchemlett.7b00233
• 作为产物：
  描述：

  ethyl 3-(4-chlorophenyl)-1,2-thiazole-4-carboxylate 在 四(三苯基膦)钯 、 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 17.34h， 生成 ethyl 3-(4-chlorophenyl)-5-methylisothiazole-4-carboxylate
  参考文献：
  名称：

  Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes

  摘要：

  We have discovered a novel series of isothiazole-based phenylpropanoic acids as GPR120 agonists. Extensive structure activity relationship studies led to the discovery of a potent GPR120 agonist 4x, which displayed good EC50 values in both calcium and beta-arrestin assays. It also presented good pharmaceutical properties and a favorable PK profile. Moreover, it demonstrated in vivo antidiabetic activity in C57BL/6 DIO mice. Studies in WT and knockout DIO mice showed that it improved glucose handling during an OGTT via GPR120. Overall, 4x possessed promising antidiabetic effect and good safety profile to be a development candidate.

  DOI：

  10.1021/acsmedchemlett.7b00233

文献信息

• [EN] ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY<br/>[FR] DÉRIVÉS D'ISOTHIAZOLE-PYRIDINE EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU HIF (FACTEUR INDUCTIBLE PAR L'HYPOXIE)
  申请人：FIBROGEN INC

  公开号：WO2009089547A1

  公开（公告）日：2009-07-16

  The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).

  本发明涉及根据公式I或II的新化合物、方法和组合物，能够降低HIF羟基酶的酶活性，从而增加缺氧诱导因子（HIF）的稳定性和/或活性。公式（I）或（II）。
• ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY
  申请人：FibroGen, Inc.

  公开号：US20150209336A1

  公开（公告）日：2015-07-30

  The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).

  本发明涉及根据式I或II的新化合物，方法和组合物，能够降低HIF羟化酶酶活性，从而增加缺氧诱导因子（HIF）的稳定性和/或活性。式（I）或（II）。
• ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY
  申请人：Zhou Xiaoti

  公开号：US20100330199A1

  公开（公告）日：2010-12-30

  The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).

  本发明涉及一种新型化合物，其符合式I或II，以及能够降低HIF羟化酶酶活性，从而增加缺氧诱导因子（HIF）的稳定性和/或活性的方法和组合物。式(I)或(II)。
• US8952160B2
  申请人：——

  公开号：US8952160B2

  公开（公告）日：2015-02-10
• US9387200B2
  申请人：——

  公开号：US9387200B2

  公开（公告）日：2016-07-12